J&J's Analgesic Sales Ease Pain Of Ongoing OTC Turnaround
This article was originally published in The Tan Sheet
Executive Summary
CFO Dominic Caruso reaffirms J&J’s commitment to keeping and growing its consumer business as the firm reports its OTC adult analgesic US market share reached 14% while pediatric share was nearly 46%.
You may also be interested in...
Tylenol Relaunch Ads Harken To “Trusted” History
In online video ads for Tylenol, the firm says “for everything we do, we know you do so much more.” CFO Dominic Caruso says the ad campaign will reconnect the brand with consumers.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.